Dr. Davuluri Rama Mohan Rao – Executive Chairman, D. Sucheth Rao – Vice Chairman & Chief Executive Officer, D. Saharsh Rao – Vice Chairman & Managing Director
Products
Pharmaceuticals, Active Pharmaceutical Ingredients (APIs), Peptides
Number of employees
1700+ (including 180 Scientists)
Neuland Laboratories Limited is an Indian publicly listed contract development and manufacturing organization (CDMO) specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and peptide APIs. Headquartered in Hyderabad, Telangana, the company was founded in 1984.[1][2][3][4] The company is publicly listed on the Bombay Stock Exchange and National Stock Exchange, and serves over 500 clients across more than 80 countries including the US, Europe, Japan, and Latin America.[5][6][7][8]
Neuland Laboratories received the CMO Leadership Award for Regulatory Excellence in 2013.[9][10]
Neuland provides end-to-end solutions for the chemical needs of the pharmaceutical industry.[11]
Product Development
Neuland operates in three primary verticals: Custom Manufacturing Solutions (CMS), Generic Drug Substances (GDS), and Peptide APIs. CMS provides API development services from pre-clinical to commercial scale, including process chemistry, analytical methods, and regulatory documentation . The GDS division manufactures non-exclusive APIs for generic drug companies. Its Peptide API unit synthesizes peptides of 3–40 amino acids, including decapeptides up to 35 kg for Phase III studies, and commercially produced a 16-amino-acid cyclic peptide via segment condensation.[12]
Among Neuland's 79 products, some of them include Esomeprazole magnesium dihydrate, Tamsulosin Hydrochloride, Esomeprazole magnesium trihydrate, Lansoprazole, Dexlansoprazole, (1R,2R)-1,2 Bis ( methane sulfonyl-oxy methyl) cyclohexane.[8]
